BioCryst appoints Vincent Milano, ex-ViroPharma CEO, to Board of Directors

BIOCRYST PHARMACEUTICALS INC

Board expanded to nine directors; Milano elected effective July 26, 2021.
Milano appointed to Audit and Finance Committees; initial grant of 66,667 stock options.
Milano is CEO of Idera Pharmaceuticals and former chairman/CEO of ViroPharma (developer of Cinryze for HAE).
He will receive compensation per director policy, including annual grants of 40,000 stock options.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Vincent J. Milano

Director

BCRX · BIOCRYST PHARMACEUTICALS INC

Effective: 2021-07-26
Filed: July 28, 2021, 7:59 PM ET

elected Vincent J. Milano to fill the vacancy created by the enlargement of the Board, effective July 26, 2021

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Vincent J. Milano was elected as Director at BIOCRYST PHARMACEUTICALS INC.

Action: elected
Role: Director

Exact text from the filing

elected Vincent J. Milano to fill the vacancy created by the enlargement of the Board, effective July 26, 2021

View on SEC.gov

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-21-005153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.